|
DRD1 |
dopamine receptor D1 |
- Dopamine receptors
- G alpha (s) signalling events
- ADORA2B mediated anti-inflammatory cytokines production
|
- Ziprasidone
- Cabergoline
- Cabergoline
- Olanzapine
- Olanzapine
- Methylergometrine
- Clozapine
- Phenylpropanolamine
- Loxapine
- Loxapine
- Imipramine
- Chlorpromazine
- Chlorpromazine
- Haloperidol
- Triflupromazine
- Amoxapine
- Lamotrigine
- Cinnarizine
- Lisuride
- Fluphenazine
- Thioridazine
- Ergotamine
- Apomorphine
- Paroxetine
- Trimipramine
- Risperidone
- Fenoldopam
- Minaprine
- Perphenazine
- Flupentixol
- Dopamine
- Dopamine
- Carphenazine
- Ergoloid mesylate
- Pergolide
- Bromocriptine
- Quetiapine
- Levodopa
- Aripiprazole
- Chlorprothixene
- Paliperidone
- Methotrimeprazine
- Periciazine
- Acepromazine
- Pipotiazine
- Thioproperazine
- Thiothixene
- Zuclopenthixol
- Iloperidone
- Rotigotine
- Lumateperone
- Mianserin
- Asenapine
- Quinagolide
- Zotepine
- Pipamperone
- Dihydro-alpha-ergocryptine
- Epicriptine
- Pipradrol
- Tetrahydropalmatine
- Dihydrexidine
- Dihydroergocristine
- Aripiprazole lauroxil
|
|
|
DSP |
desmoplakin |
- Apoptotic cleavage of cell adhesion proteins
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
- Zinc
- Artenimol
- Zinc acetate
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
- Striate palmoplantar keratoderma
- Skin fragility-woolly hair syndrome
- Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
|
|
EEF2K |
eukaryotic elongation factor 2 kinase |
- mTORC1-mediated signalling
|
|
|
|
EGFR |
epidermal growth factor receptor |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Signaling by ERBB4
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- PLCG1 events in ERBB2 signaling
- PIP3 activates AKT signaling
- Signaling by EGFR
- GRB2 events in EGFR signaling
- GAB1 signalosome
- SHC1 events in EGFR signaling
- EGFR downregulation
- GRB2 events in ERBB2 signaling
- PI3K events in ERBB2 signaling
- EGFR interacts with phospholipase C-gamma
- EGFR Transactivation by Gastrin
- Constitutive Signaling by Aberrant PI3K in Cancer
- Signal transduction by L1
- Constitutive Signaling by EGFRvIII
- Inhibition of Signaling by Overexpressed EGFR
- RAF/MAP kinase cascade
- ERBB2 Regulates Cell Motility
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- ERBB2 Activates PTK6 Signaling
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- PTK6 promotes HIF1A stabilization
- Downregulation of ERBB2 signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- Extra-nuclear estrogen signaling
- NOTCH3 Activation and Transmission of Signal to the Nucleus
- HCMV Early Events
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
|
- Cetuximab
- Lidocaine
- Gefitinib
- Erlotinib
- Lapatinib
- Panitumumab
- Alvocidib
- IGN311
- Matuzumab
- Vandetanib
- Rindopepimut
- Canertinib
- Pelitinib
- Varlitinib
- AV-412
- S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
- PD-168393
- Afatinib
- Osimertinib
- Necitumumab
- Foreskin keratinocyte (neonatal)
- Depatuxizumab mafodotin
- Icotinib
- Neratinib
- Dacomitinib
- Fostamatinib
- Zalutumumab
- Brigatinib
- Olmutinib
- Zanubrutinib
- Abivertinib
|
- Choriocarcinoma
- Gastric cancer
- Bladder cancer
- Oral cancer
- Glioma
- Laryngeal cancer
- Cervical cancer
- Esophageal cancer
|
|
ERBB3 |
erb-b2 receptor tyrosine kinase 3 |
|
|
- Lethal congenital contractural syndrome (LCCS)
- Type I diabetes mellitus
|
|
ESR1 |
estrogen receptor 1 |
- Nuclear signaling by ERBB4
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
- RUNX1 regulates estrogen receptor mediated transcription
- ESR-mediated signaling
- RUNX1 regulates transcription of genes involved in WNT signaling
- Regulation of RUNX2 expression and activity
- Regulation of RUNX2 expression and activity
- Extra-nuclear estrogen signaling
- Estrogen-dependent gene expression
|
- Diethylstilbestrol
- Chlorotrianisene
- Conjugated estrogens
- Desogestrel
- Levonorgestrel
- Progesterone
- Lindane
- Raloxifene
- Toremifene
- Medroxyprogesterone acetate
- Testosterone
- Mitotane
- Estrone
- Tamoxifen
- Hexachlorophene
- Estradiol
- Ethynodiol diacetate
- Dobutamine
- Clomifene
- Dienestrol
- Fulvestrant
- Norgestimate
- Ethinylestradiol
- Melatonin
- Trilostane
- Naloxone
- Fluoxymesterone
- Estramustine
- Mestranol
- Danazol
- Oxybenzone
- Allylestrenol
- Zinc
- Genistein
- Prasterone
- Benzophenone
- Equilin
- Compound 19
- Resveratrol
- Compound 18
- Phthalic Acid
- Pyrazole
- Stanolone
- Naringenin
- Compound 4-D
- 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Quercetin
- Afimoxifene
- 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
- Estriol
- Estrone sulfate
- Quinestrol
- Phenolphthalein
- Permethrin
- Ospemifene
- AP1081
- Custirsen
- NP-50301
- CHF 4227
- TAS-108
- Lasofoxifene
- Arzoxifene
- Elacestrant
- Bazedoxifene
- Methyltestosterone
- beta-Naphthoflavone
- 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
- 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
- [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
- (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
- (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
- 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
- Hexestrol
- dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
- Erteberel
- N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
- 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
- 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
- DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
- 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
- 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
- (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
- 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
- Tibolone
- Eugenol
- Synthetic Conjugated Estrogens, A
- Synthetic Conjugated Estrogens, B
- Polyestradiol phosphate
- Norethynodrel
- Octocrylene
- Homosalate
- Enzacamene
- Zeranol
- Ractopamine
- Gestrinone
- Propyl Gallate
- 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
- Testosterone cypionate
- Testosterone enanthate
- Testosterone undecanoate
- Stanolone acetate
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
- Estriol tripropionate
- Fluoroestradiol F-18
|
|
|
ETV1 |
ETS variant transcription factor 1 |
|
|
- Ewing's sarcoma
- Prostate cancer
|
|
FBXW11 |
F-box and WD repeat domain containing 11 |
- Activation of NF-kappaB in B cells
- Downstream TCR signaling
- Regulation of PLK1 Activity at G2/M Transition
- FCERI mediated NF-kB activation
- Dectin-1 mediated noncanonical NF-kB signaling
- CLEC7A (Dectin-1) signaling
- NIK-->noncanonical NF-kB signaling
- MAP3K8 (TPL2)-dependent MAPK1/3 activation
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
FOS |
Fos proto-oncogene, AP-1 transcription factor subunit |
- Oxidative Stress Induced Senescence
- Senescence-Associated Secretory Phenotype (SASP)
- FCERI mediated MAPK activation
- Activation of the AP-1 family of transcription factors
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- Estrogen-dependent gene expression
- NGF-stimulated transcription
- NGF-stimulated transcription
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- Pseudoephedrine
- Nadroparin
|
|
|
FXYD1 |
FXYD domain containing ion transport regulator 1 |
- Ion homeostasis
- Ion transport by P-type ATPases
- Potential therapeutics for SARS
|
|
|
|
GABRB3 |
gamma-aminobutyric acid type A receptor subunit beta3 |
- Signaling by ERBB4
- GABA receptor activation
- GABA receptor activation
|
- Lorazepam
- Ethchlorvynol
- Enflurane
- Temazepam
- Butabarbital
- Butalbital
- Phenytoin
- Etomidate
- Talbutal
- Pentobarbital
- Clobazam
- Meprobamate
- Eszopiclone
- Alprazolam
- Lindane
- Metharbital
- Chlordiazepoxide
- Amoxapine
- Adinazolam
- Lamotrigine
- Piperazine
- Ivermectin
- Medroxyprogesterone acetate
- Clorazepic acid
- Acamprosate
- Midazolam
- Flurazepam
- Isoflurane
- Primidone
- Halazepam
- Propofol
- Propofol
- Diazepam
- Oxazepam
- Triazolam
- Ethanol
- Methoxyflurane
- Memantine
- Clonazepam
- Methyprylon
- Halothane
- Desflurane
- Flumazenil
- Estazolam
- Sevoflurane
- Glutethimide
- Camazepam
- Delorazepam
- Flunitrazepam
- Ethyl loflazepate
- Cloxazolam
- Bromazepam
- Clotiazepam
- Fludiazepam
- Ketazolam
- Prazepam
- Quazepam
- Cinolazepam
- Nitrazepam
- Prasterone
- Taurine
- Fospropofol
- Brotizolam
- Stiripentol
- Etizolam
- Thiocolchicoside
- Brexanolone
- Apalutamide
- Remimazolam
- Muscimol
- Benzodiazepine
- Pinazepam
- Medazepam
- Loprazolam
- Doxefazepam
- Lormetazepam
- Nordazepam
- Oxazepam acetate
- Cinazepam
- Bentazepam
- Mexazolam
|
|
|
GABRR1 |
gamma-aminobutyric acid type A receptor subunit rho1 |
|
- Lindane
- Picrotoxin
- Fludiazepam
|
|
|
GAD1 |
glutamate decarboxylase 1 |
- GABA synthesis
- GABA synthesis, release, reuptake and degradation
- MECP2 regulates transcription of genes involved in GABA signaling
|
- Pyridoxal phosphate
- Pyridoxal phosphate
- Glutamic acid
|
|
|
GAD2 |
glutamate decarboxylase 2 |
- GABA synthesis
- GABA synthesis, release, reuptake and degradation
- MECP2 regulates transcription of genes involved in GABA signaling
|
- Pyridoxal phosphate
- Glutamic acid
|
|
|
GFAP |
glial fibrillary acidic protein |
- Nuclear signaling by ERBB4
- Chaperone Mediated Autophagy
|
|
|
|
GJA5 |
gap junction protein alpha 5 |
|
|
|
|
GJB1 |
gap junction protein beta 1 |
- Oligomerization of connexins into connexons
- Oligomerization of connexins into connexons
- Transport of connexins along the secretory pathway
- Gap junction assembly
|
|
- Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
|
|
GLI1 |
GLI family zinc finger 1 |
- Degradation of GLI1 by the proteasome
- Degradation of GLI1 by the proteasome
- Hedgehog 'off' state
- Hedgehog 'on' state
- GLI proteins bind promoters of Hh responsive genes to promote transcription
|
|
|
|
GMFB |
glia maturation factor beta |
|
|
|
|
GNA13 |
G protein subunit alpha 13 |
- NRAGE signals death through JNK
- Rho GTPase cycle
- G alpha (12/13) signalling events
- Thromboxane signalling through TP receptor
- Thrombin signalling through proteinase activated receptors (PARs)
- Thrombin signalling through proteinase activated receptors (PARs)
|
|
|